Performing a systematic review and meta-analysis to evaluate the diagnostic performance of the total prostate-specific antigen (tPSA) tests for diagnosis of prostate cancer among Chinese. Literatures related to diagnosis of prostate cancer by tPSA and the ratio of free to total PSA (f/tPSA) being retrieved in five electronic databases. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio (DOR) were pooled using random effects models. Summary receiver operating characteristic curves (SROC) used to summarize overall test performance. In total 10 studies meting the inclusion criteria, 2256 patients were included. Among them 423 were patients of prostate cancer compared to 1833 were patients of benign prostate hyperplasia (BPH). The pooled sensitivity and specificity of tPSA44.0 ng/ml, tPSA410.0 ng/ml and f/tPSAo0.15 as threshold for the diagnosis of prostate cancer were heterogeneity. The areas under SROC (AUC) were 80, 85 and 87%, respectively (Po0.05). The pooled DOR were 8.44(95%CI: 4.45B16.00), 9.94(95%CI: 4.15B23.77) and 13.75(95%CI: 6.35B29.76), respectively (Po0.05). v 2 test used for testing the heterogeneity. tPSA and f/tPSA made an important performance for diagnosis of prostate cancer in decade among Chinese. The use of f/tPSAo0.15 as threshold maintain a high prognostic accuracy for prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed cancer among men in many Western countries. 1 Traditionally, it has been thought that the incidence of prostate cancer in China and other Asian countries is low. 2 The most widely used indicator to detect prostate cancer in the general population is a serum measurement of PSA, a serine protease produced by the prostate epithelium. It recommended in USA and Europe that the positive serum tPSA candidates, whose serum tPSA value is 44.0 ng/ml, should be subject to transrectal ultrasoundguided prostate needle-biopsy. 3 What is the performance of PSA for prostate cancer in Chinese, the lower incidence country? A systematic review and metaanalysis were performed to determine the diagnostic ability of PSA tests for prostate cancer in Chinese.
Materials and methods

Search strategy and selection criteria
Relevant published papers were identified by searching computerized bibliographic systems such as MEDLINE, the Cochrane Library database, Chinese Biomedical Database (CBMD), Chinese Medical Current Contents (CMCC), China National Knowledge Infrastructure (CNKI), from January 1995 to December 2005. A search strategy used the following words: prostate cancer, diagnosis, prostatespecific antigen, sensitivity and specificity. Consulting experts found additional papers or hand searching the reference lists of relevant papers. Only reports in English or Chinese were eligible for the searching.
We followed a written protocol and explicit study selection criteria. Studies were included in the review if they met the following criteria: (a) comparison of PSA test between patients with prostate cancer and BPH; (b) data necessary for the computation of both sensitivity and specificity; (c) transrectal ultrasound-guided prostate needle-biopsy or post-operation pathology checking as the reference standard; (d) blood was sampled prior to prostate manipulation or biopsy.
Data abstraction and quality assessment
Two reviewers (Sun Guang and Wang Yi) independently screened the titles, abstracts and full text to identify eligible studies. Disagreements between the reviewers were resolved by consensus. Data retrieved from the studies included methodological quality and outcome data (sensitivity and specificity). We assessed the quality of the studies by using criteria selected from the QUADAS checklist for assessment of quality of diagnostic studies.
Statistical analysis
Our analyses focused on the following measures of diagnostic accuracy: sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and DOR. We summarized the joint distribution of sensitivity and specificity using SROC. The area under curve (AUC) present an overall summary of test performance and a global measure of overall test accuracy. An AUC of 100% indicates perfect discriminatory ability. Random effects models used to estimate overall sensitivity and specificity, and a w 2 test for heterogeneity between studies. These analyses were undertaken using Meta-Disc statistical software (version 1.1.1). 5 Excel 2003 was also used for this analysis.
Results
Description characters and quality assessment of included studies The quality of the studies was assessed by using criteria selected from the QUADAS checklist for assessment of quality of diagnostic studies: study design (cross-sectional versus case-control), blinding (blind versus not interpretation of index test), study size (420 positive specimens or not), et al. (Table 3) .
Results of meta-analysis
We identified 10 studies that assessed the sensitivity of tPSA value 44.0 ng/ml, tPSA value 410.0 ng/ml and f/ tPSAo0.15 as the threshold. Sensitivity is the proportion of patients with pathology-proven prostate cancer who are positive by PSA test. As seen in Table 1 , the The entire heterogeneity test used w 2 test. Specificity is the proportion of individuals without prostate cancer (pathology-proven negative) who are negative by the PSA test. Ten studies assessed the specificity of tPSA44.0 ng/ml, tPSA410.0 ng/ml and f/tPSAo0.15 as the threshold, the specificity range of the three thresholds were, respectively (0.10-0.72), (0.56-0.94) and (0.54-0.93), all test of heterogeneity showed significantly (Po0.001). The pooled specificity were 0.58(95%CI: 0.55B0.60), 0.87(95% CI: 0.85B0.88), 0.82(95%CI: 0.80B0.83), respectively.
Summary of prognostic accuracy
Figures 1-3 presents the sensitivity and specificity estimates in a SROC curve. Owing to the significantly heterogeneity of sensitivity and specificity, asymmetrical SROC cure was used for pooling. The curve shows that most studies had high specificity with lower and variable estimates of sensitivity. The AUC of tPSA44.0 ng/ml, Performance of tPSA and f/tPSA for prostate cancer in Chinese Y Wang et al tPSA410.0 ng/ml and f/tPSAo0.15 were 80, 85 and 87%, respectively. The diagnostic odds ratio (DOR) expresses how much greater the odds of having the disease are for the people with a positive test result than for the people with a negative test result. It is a single measure of diagnostic test performance that combines both likelihood ratios. In Table 4 , the pooled DOR of tPSA44.0 ng/ml, tPSA410.0 ng/ml and f/tPSAo0. 15 
Discussion
Serum value of tPSA44.0 ng/ml has limited specificity because such elevations also occur in men with benign disease (e.g. prostatic hyperplasia and prostatitis). It is well known that PSA values for prostate cancer and benign prostate hyperplasia have considerable overlap. Reducing the PSA cutoff point from 10.0 ng/ml to 4.0 ng/ml can increase the sensitivity, from 0.65(95%CI: 0.61B0.70) to 0.90(95%CI: 0.87B0.93), but doing that will further reduce the specificity, from 0.87(95%CI: 0.85B0.88) to 0.58(95%CI: 0.55B0.60). The pooled sensitivity of f/tPSAo0.15 was 0.69(95%CI: 0.64B0.73), and the pooled specificity 0.82(95%CI: 0.80B0.83), had the similar result to the tPSA410.0 ng/ml. A prior systematic study, 16 showed that f/tPSAo0.15 had a relative high sensitivity and specificity with tPSA levels from 4.0 ng/ ml to 10.0 ng/ml.
To evaluate the overall accuracy of the PSA test for the diagnosis of prostate cancer, we introduced the asymmetric SROC curve and AUC. Although the AUC of tPSA value 410.0 ng/ml and f/tPSAo0.15 were 0.85 and 0.87, significant heterogeneity in the sensitivity estimates precluded the determination of clinically meaningful summary estimates of accuracy. The AUC showed that tPSA value 410.0 ng/ml and f/tPSAo0.15 had the When the tPSA level was 410.0 ng/ml, test of f/ tPSAo0.15 and tPSA410.0 ng/ml as threshold for diagnosis of prostate cancer had similar accuracy. However, when the tPSA level was in the diagnostic 'grey zone', between 4.0 ng/ml and 10.0 ng/ml, test of f/tPSAo0.15 revealed the predominance. Considered above all, test of f/tPSAo0.15 is a suitable cutoff for the diagnosis of prostate cancer in Chinese men nowadays.
As the outcome data used in this study based on retrospective observational studies, there would be considerable variation for the results of primary studies. Furthermore, it was proved that 10 studies were heterogeneous with a statistical significance for both tPSA44.0 ng/ml, tPSA410.0 ng/ml and f/tPSAo0.15. This heterogeneity may have been caused by chance alone (the small sample size), but it can also reflect true heterogeneity. Also may have been introduced by the exclusion of non-English and Chinese language studies. Although we explored the issue of heterogeneity using randomized effective models and asymmetric SROC for analyses, techniques such as metaregression may be useful in the evaluation of heterogeneity could not performed because of the small sample size included in our systematic review.
Conclusion
TPSA and f/tPSA made an important performance for diagnosis of prostate cancer in decade among Chinese. The use of f/tPSAo0.15 as threshold maintain a high prognostic accuracy for prostate cancer.
